All News

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
grappa sign treatment recommendations

New GRAPPA 2021 PsO and PsA Treatment Recommendations

Rachel Tate, DO

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.

Read Article
RNL, over, microphone

RheumNow Live 2021 Now Available for All

Jack Cush, MD

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

Read Article
cost.price_.biologic.injectable.jpg

Insurers Bet Big on Bribing Patients

Madelaine Feldman, MD, and Jay Salliotte

Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division.

Read Article
RheumNow Podcast square

RheumNow Podcast – Falling or Falling in Love?

Jack Cush, MD

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Read Article
2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.

Eric Dein ejdein1 ( View Tweet)

IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy? ⭐️Phase II study - no difference in rotator cuff score (WORC) vs placebo ⭐️no difference in pain score Abs#POS0022 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus ⭐️⬇️AS activity w/ or w/o MRI sacroilitis Abs#OP0142 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021. “SpA” talk by Prof. Désirée van der Heijde. Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏 /TK https://t.co/JFr3VC8sXY
ARD & RMD Open ARD_BMJ ( View Tweet)
COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts treated w/ ADA re-randomized to IXE showed further⬇️in SP-N & spinal pain. Poster #POS0901 #EULAR2021 @RheumNow https://t.co/46qiqrohbX https://t.co/uB15oTwztV

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (normal CRP & MRI ) showed ASA40 response w/ ixekizumab @RheumNow https://t.co/5KT8A81auq
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
New download available! Difficult RA Defined https://t.co/6WGMEiwiUk https://t.co/VTCm4cuyRe

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is Up! – with news of Uppers and Downers. Read about Vaccine success, CKD gout prophylaxis, TOFA in AS & too much IL-17 inhib can be a problem https://t.co/kt63YrQ0Sw Listen iTunes> https://t.co/FHJv01AAbC or Android SoundCloud>>https://t.co/IyYvjkWUc1

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×